nelfinavir has been researched along with Cancer of Cervix in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Charnalia, M; Chopra, S; Deodhar, K; Engineer, R; Ghosh, J; Goda, JS; Gota, V; Gulia, S; Gupta, S; Kannan, S; Krishnamurthy, MN; Mahantshetty, U; Menon, S; Mittal, P; Mulani, J; Naidu, L; Pai, V; Pant, S; Popat, P; Rangarajan, V; Rath, S; Sawant, S; Shah, S; Thakkar, P | 1 |
| Garcia-Soto, AE; Hu, JJ; Jimenez, EA; Kossenkov, A; Lin, LL; Lucci, JA; Maity, A; McKenzie, ND; Mills, GB; Pearson, JM; Portelance, L; Qureshi, R; Schwartz, L; Simpkins, F; Whicker, ME | 1 |
| Chen, R; He, Z; Jiang, S; Liang, S; Xia, C; Xiao, G; Xu, W; Yang, J | 1 |
| Du, L; Jiang, S; Pham, P; Xiang, T; Zhu, B | 1 |
| Davis, MA; Delaney, JR; Patel, CB; Storgard, R; Stupack, DG | 1 |
| Chen, J; Chen, R; Du, L; Jiang, S; Pan, Y; Qi, Q; Xia, C; Xiao, G | 1 |
| Bruning, A; Burges, A; Friese, K; Mylonas, I; Vogel, M | 1 |
2 trial(s) available for nelfinavir and Cancer of Cervix
| Article | Year |
|---|---|
Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial.
Topics: Adult; Brachytherapy; Clinical Trials, Phase III as Topic; Female; Humans; Middle Aged; Nelfinavir; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-akt; Quality of Life; Uterine Cervical Neoplasms | 2022 |
Phase 1 trial of nelfinavir added to standard cisplatin chemotherapy with concurrent pelvic radiation for locally advanced cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Female; Humans; Nelfinavir; Uterine Cervical Neoplasms | 2021 |
5 other study(ies) available for nelfinavir and Cancer of Cervix
| Article | Year |
|---|---|
Metformin combined with nelfinavir induces SIRT3/mROS-dependent autophagy in human cervical cancer cells and xenograft in nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Female; HeLa Cells; HIV Protease Inhibitors; Humans; Hypoglycemic Agents; Metformin; Mice; Mice, Inbred BALB C; Mice, Nude; Nelfinavir; Reactive Oxygen Species; Sirtuin 3; Tumor Burden; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Female; HIV Protease Inhibitors; Humans; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Nelfinavir; Reactive Oxygen Species; Uterine Cervical Neoplasms | 2015 |
Nelfinavir is effective against human cervical cancer cells in vivo: a potential treatment modality in resource-limited settings.
Topics: Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Female; Humans; Nelfinavir; Uterine Cervical Neoplasms | 2016 |
Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Female; Heterografts; Humans; Metformin; Mice, Nude; Nelfinavir; Neoplasm Transplantation; Treatment Outcome; Uterine Cervical Neoplasms | 2017 |
Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Caspases; Cell Cycle; Drug Synergism; Female; HIV Protease Inhibitors; Humans; Membrane Potential, Mitochondrial; Nelfinavir; Proteasome Inhibitors; Pyrazines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2011 |